METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): CLINICAL SIGNIFICANCE OF THE NEW NOMENCLATURE AND NON-INVASIVE DIAGNOSIS
Keywords:
Materials and methods. A multisociety Delphi consensus statement (2023), the EASL–EASD–EASO clinical practice guidelines (2024) and a meta-analysis of global epidemiology (2023) were comparatively analysed.Abstract
Relevance. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide: according to a meta-analysis of 92 studies involving more than 9 million individuals, its global prevalence is 30.1%, having risen from 25.3% in 1990–2006 to 38.2% in 2016–2019 [1]. In 2023, the nomenclature of the disease was revised, which requires updated approaches to diagnosis and risk assessment in clinical practice.
References
1.Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. doi:10.1097/HEP.0000000000000004
2.Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–1556. doi:10.1016/j.jhep.2023.06.003
3.European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. doi:10.1016/j.jhep.2024.04.031